Program - Society of Toxicology

More documents

Recommendations

Info

44 th Annual Meeting and ToxExpo Program Description TUESDAY Tuesday Afternoon, March 8 1:30 PM to 4:30 PM Room RO8 SYMPOSIUM SESSION: UPDATE ON MECHANISMS FOR ENVIRONMENTAL TOBACCO SMOKE-INDUCED HEALTH EFFECTS Chairperson(s): Chris A. Pritsos, University of Nevada, Reno, NV and Kevin E. Pinkerton, University of California, Davis, Davis, CA. Endorsed by: Occupational and Public Health SS Risk Assessment SS Epidemiological evidence has demonstrated an association between exposure to environmental tobacco smoke (ETS) and disease. Diseases associated with ETS exposure include a variety of cancers, cardiovascular disease, COPD, asthma and a number of perinatal manifestations, to name a few. While many of these exposure/disease associations are strong, the mechanism(s) by which ETS exposure influences the etiology of these diseases remains unclear. There are a great number of confounding factors which make ascribing any ETS-induced mechanism for disease difficult. Included amongst these factors is the immense complexity of the substituents which make up ETS. ETS is comprised of both a vapor phase and particulate phase with over 4000 chemicals identified to date. One must not only consider the effect of individual compounds but must also consider potential synergism between compounds. Another factor which needs to be considered is the fact that exposure to tobacco smoke compounds is substantially less than for smokers, due to dilution of the smoke. Chemical reactivity or “aging” of the ETS components can also modify their chemical nature. Also, an individual’s susceptibility to the harmful effects of ETS exposure can be greatly influenced by their genetic makeup. While quite complex, certain mechanistic themes are beginning to emerge as characteristic of ETS’s association with these diseases. The speakers will provide recent advances in our understanding of the mechanisms by which ETS can influence the etiology of these diseases and provide a linkage between the epidemiological and biochemical/pathophysiological bases of disease. The symposium will have two presentations each dealing with: ETS and cardiovascular disease, ETS and cancer and ETS and respiratory diseases. #1008 1:30 UPDATE ON MECHANISMS FOR ENVIRONMENTAL TOBACCO SMOKE- INDUCED HEALTH EFFECTS. C. A. Pritsos 1 and K. E. Pinkerton 2 . 1 Nutrition, University of Nevada, Reno, NV and 2 Center for Health and the Environment, University of California, Davis, CA. #1009 1:35 IMPACT OF WORKPLACE ETS EXPOSURE ON RISK FACTORS FOR CORONARY HEART DISEASE. C. A. Pritsos 1 , G. R. Cutter 2 , S. St. Jeor 3 , J. A. Ashley 1 , S. Perumean-Chaney 2 , S. Clodfelter 1 , J. E. Woodrow 1 , A. C. Collier 1 , L. D. Bowen 1 , N. J. Martin 1 and K. L. Pritsos 1 . 1 Nutrition, University of Nevada, Reno, NV, 2 Biostatistics, University of Alabama, Birmingham, Birmingham, AL and 3 Internal Medicine, University of Nevada, Reno, NV. #1010 2:00 IMPACT OF PRENATAL CARDIOVASCULAR DISEASE RISK FACTOR EXPOSURE ON MITOCHONDRIAL DAMAGE AND ADULT HEART DISEASE DEVELOPMENT. S. W. Ballinger 1 , Z. Yang 1 and A. Penn 2 . 1 Pathology, University Alabama at Birmingham, Birmingham, AL and 2 Veterinary Medicine, Louisiana State University, Baton Rouge, LA. #1011 2:30 IMMUNOLOGIC DETECTION OF CARCINOGEN-DNA AND PROTEIN ADDUCTS. R. M. Santella. Environmental Health Sciences, Columbia University, New York. #1012 3:00 ETS IMPACT ON ALLERGIC AIRWAYS RESPONSES TO ANTIGEN. A. penn 1 , D. Paulsen 2 and D. Horohov 3 . 1 CBS, LSU Vet.Med., Baton Rouge, LA, 2 PBS, LSU Vet.Med., Baton Rouge, LA and 3 Vet. Sciences., University of KY, Lexington, KY. #1013 3:30 GESTATIONAL STAGE-SPECIFIC ETS- INDUCED OXIDATIVE DNA DAMAGE. L. M. Anderson 1 , A. Maciag 1 , I. Espiritu 2 , A. Bialkowska 1 , K. Kasprzak 1 and H. Witschi 2 . 1 Lab. Comparative Carcinogenesis, National Cancer Inst., Frederick, MD and 2 Center for Health and the Environment, University of California, Davis, CA. #1014 4:00 EFFECTS OF ENVIRONMENTAL TOBACCO SMOKE ON CYTOKINES AND NEUROTROPHINS IN THE NEONATAL LUNG. K. E. Pinkerton, J. P. Joad and M. Yu. Center for Health and the Environment, University of California, Davis, CA. Abstract 1015 is located on page 150. Tuesday Afternoon, March 8 1:30 PM to 4:30 PM Room 220 WORKSHOP SESSION: CURRENT AND FUTURE SCIENCE-BASED APPROACHES TO DRUG SAFETY EVALUATION: AN ASSESSMENT OF POTENTIAL CANCER RISK Chairperson(s): Martha M. Moore, U.S. FDA, Jefferson, AR and David Jacobson-Kram, U.S. FDA, Rockville, MD. Endorsed by: Carcinogenesis SS* Regulatory and Safety Evaluation SS Risk Assessment SS Student Advisory Committee Currently the preclinical safety evaluation of pharmaceuticals for potential cancer risk includes the application of genetic toxicology assays and the rodent cancer bioassay. While data from rodent carcinogenicity studies are generally available prior to marketing approval, data from short-term studies is used to assess cancer risk during the drug development phases. Although this has generally been a successful approach there is wide discussion as to the appropriate role of the genetic toxicology assays and the possibility that other assays such as the Syrian hamster embryo (SHE) test and the shorter term transgenic cancer bioassays (Trp53 and rasH2) might be useful. The emerging “omics” technologies provide for possible new and improved approaches to understanding whether new drugs might cause an increased cancer risk. In addition, both present and future technologies have the potential to be applied within the context of the clinical trials. This session will provide a forum to discuss these issues. The first speaker will provide an overview of the current approaches and issues relevant to preclinical drug safety assessment. Additional speakers will discuss the current thinking on the use of genetic toxicology assays, the SHE assay and the transgenic cancer bioassays. The last two speakers will consider both the present and potential future applications of “omic” technologies and our ability to utilize individuals in clinical trials to provide a better assessment of the potential human cancer risk from pharmaceutical drugs. 128 SOT’s 44 th Annual Meeting
44 th Annual Meeting and ToxExpo Program Description #1025 1:30 CURRENT AND FUTURE SCIENCE-BASED APPROACHES TO DRUG SAFETY EVALUATION: AN ASSESSMENT OF POTENTIAL CANCER RISK. M. Moore. DGRT, NCTR, Jefferson, AR. #1026 1:35 OVERVIEW OF THE CANCER SAFETY ASSESSMENT IN CDER/FDA. A. Jacobs. U.S. FDA, Rockville, MD. #1027 2:10 THE ROLE OF GENETIC TOXICOLOGY ASSAYS IN A WEIGHT-OF-WVIDENCE CANCER ASSESSMENT FOR NEW PHARMACEUTICALS. D. Jacobson-Kram 1 . 1 FDA, Rockville, MD and 2 Office of New Drugs, Center for Drug Evaluation and Research, U.S. FDA, Rockville, MD. #1028 2:45 TRANSGENIC CANCER BIOASSAYS: A USEFUL ADDITION TO CANCER SAFETY ASSESSMENT OF NEW PHARMACEUTICALS? R. D. Storer. Safety Assessment, Merck Research Laboratories, West Point, PA. #1029 3:20 INTEGRATION OF OMIC DATA INTO CANCER RISK ASSESSMENT. Y. Dragan. Hepatic Toxicology, NCTR, Jefferson, AR. #1030 3:55 CANCER BIOMARKERS: CAN THEIR APPLICATION IN CLINICAL TRIALS IMPROVE THE SAFETY ASSESSMENT OF NEW PHARMACEUTICALS? R. J. Albertini. Genetic Toxicology Lab., University of Vermont, Burlington, VT. Sponsor: M. Moore. Tuesday Afternoon, March 8 1:30 PM to 4:30 PM Room RO3 WORKSHOP SESSION: MOLECULAR PATHWAYS TO TOXICANT- INDUCED OSTEOPOROSIS Chairperson(s): Maryka Bhattacharyya, Argonne National Laboratory, Argonne, IL and Edward Puzas, University of Rochester School of Medicine, Rochester, NY. Endorsed by: Mechanisms SS Metals SS* Student Advisory Committee Women in Toxicology SS Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility and an increased susceptibility to fractures of the hip, spine, and wrist. This disease is responsible for more than 1.5 million fractures annually; 44 million Americans have low bone mass such that they either have osteoporosis or are at significant risk of developing the disease. Of the 10 million who actually have osteoporosis, 80 percent are women. Men suffer one-third of all hip fractures that occur, and approximately one-third of these men will not survive more than one year after the fracture. Our population is increasing in the fraction of elderly persons faster than at any other time in human history. Understanding ways in which toxicants contribute to the development of osteoporosis is an important undertaking. In this workshop, we will provide 1) basic information on pathways of bone formation and bone resorption and their role in the development of osteoporosis, 2) new insights into how the important metals, lead and cadmium, affect bone cell pathways and contribute to metabolic bone disease, 3) the role that alcohol consumption may play in the development of osteoporosis, and 4) discussion by workshop participants of the results presented with respect to their application and relevance to human health. #1031 1:30 MOLECULAR PATHWAYS TO TOXICANT- INDUCED OSTEOPOROSIS. M. H. Bhattacharyya 1 , E. Puzas 2 , J. B. Lian 3 , D. J. Novack 4 and M. J. Ronis 5 . 1 Biosciences Division, Argonne National Laboratory, Argonne, IL, 2 University of Rochester School of Medicine, Rochester, NY, 3 University of Massachusetts Medical School, Worcester, MA, 4 Washington University School of Medicine, St. Louis, MO and 5 University of Arkansas Medical Sciences, Little Rock, AR. #1032 1:35 MOLECULAR PATHWAYS REGULATING OSTEOBLAST GROWTH AND DIFFERENTIATION. J. B. Lian and G. S. Stein. Department of Cell Biology and Cancer Center, University of Massachusetts Medical School, Worcester, MA. Sponsor: M. Bhattacharyya. #1033 2:05 MOLECULAR PATHWAYS REGULATING OSTEOCLAST DIFFERENTIATION AND FUNCTION. D. Novack. Medicine/Bone and Mineral, Washington University School of Medicine, St. Louis, MO. Sponsor: M. Bhattacharyya. #1034 2:35 LEAD-INDUCED OSTEOPOROSIS. J. E. Puzas. Department of Orthopaedics, University of Rochester School of Medicine, Rochester, NY. #1035 3:05 FROM ITAI-ITAI TO OSTEOCLASTS: PATHWAYS TO CADMIUM-INDUCED BONE LOSS. M. H. Bhattacharyya, A. Regunathan and D. A. Glesne. Biosciences Division, Argonne National Laboratory, Argonne, IL. TUESDAY up-to-date information at www.toxicology.org 129
Page 1 and 2:
44 th Annual Meeting & ToxExpo TM P
Page 3 and 4:
Contents Program Overview .........
Page 5 and 6:
Annual Meeting Events Calendar (Con
Page 7 and 8:
Annual Meeting Events Calendar (Con
Page 9 and 10:
44 th Annual Meeting and ToxExpo Ne
Page 11 and 12:
44 th Annual Meeting and ToxExpo Co
Page 13 and 14:
Sheraton Hotel Map 44 th Annual Mee
Page 15 and 16:
Itinerary Planner Computer Stations
Page 17 and 18:
2005 Exhibitors (Continued) 44 th A
Page 19 and 20:
44 th Annual Meeting and ToxExpo To
Page 21 and 22:
44 th Annual Meeting and ToxExpo Ex
Page 23 and 24:
General Information 44 th Annual Me
Page 25 and 26:
44 th Annual Meeting and ToxExpo Ge
Page 27 and 28:
44 th Annual Meeting and ToxExpo Ge
Page 29 and 30:
2005 Award Winners The Society of T
Page 31 and 32:
2005 Award Winners (Continued) Enha
Page 33 and 34:
2004 Student Award Winners Colgate-
Page 35 and 36:
44 th Annual Meeting and ToxExpo Sc
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
INTERNATIONAL HARMONIZATION OF TECH
Page 49 and 50:
Saturday Afternoon, March 5 2:00 PM
Page 51 and 52:
44 th Annual Meeting and ToxExpo Pr
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80: 44 th Annual Meeting and ToxExpo Pr
Page 129: 44 th Annual Meeting and ToxExpo Pr
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
44 th Annual Meeting and ToxExpo #1
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Author Index 44 th Annual Meeting a
Page 229 and 230:
Author Index (Continued) 44 th Annu
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
SOT Affiliates for 2005 44 th Annua
Page 249 and 250:
44 th Annual Meeting and ToxExpo 20
Page 251 and 252:
Headquarters Staff 44 th Annual Mee
Page 253 and 254:
44 th Annual Meeting and ToxExpo Ap
Page 255 and 256:
44 th Annual Meeting and ToxExpo Of
Page 257 and 258:
44 th Annual Meeting and ToxExpo So
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
up-to-date information at www.toxic
Page 267 and 268:
44 th Annual Meeting and ToxExpo To
Page 269:
44 th Annual Meeting & ToxExpo TM M
show all

Program - Society of Toxicology

Create successful ePaper yourself

Delete template?

Save as template?